|
Delayed
NSE India S.E.
00:03:53 2026-09-09 EDT
|
5-day change | 1st Jan Change | ||
| 12.19 INR | +0.33% |
|
-0.97% | -37.20% |
| 08-15 | Nectar Lifesciences Limited Changes Its Corporate Office in Chandigarh | CI |
| 08-14 | Nectar Lifesciences Limited Announces Board and Committee Changes, Effective August 14, 2026 | CI |
| Fiscal Period: March | 2017 (INR) | 2018 (INR) | 2019 (INR) | 2020 (INR) | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.66 | -0.14 | 2.64 | -2.61 | -5.21 | |||||
Return on Total Capital | 3.25 | -0.17 | 3.28 | -3.41 | -6.56 | |||||
Return On Equity % | 2.33 | -2.25 | 0.47 | -11.23 | -7.46 | |||||
Return on Common Equity | 2.33 | -2.25 | 0.47 | -11.23 | -7.46 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 26.71 | 23.92 | 28.61 | 16.88 | - | |||||
SG&A Margin | 4.57 | 5.22 | 5.14 | 5.9 | - | |||||
EBITDA Margin % | 9.5 | 3.54 | 9.09 | -1.56 | - | |||||
EBITA Margin % | 6.56 | 0.25 | 6.16 | -4.57 | - | |||||
EBIT Margin % | 6.09 | -0.34 | 5.49 | -5.3 | - | |||||
Income From Continuing Operations Margin % | 1.5 | -1.59 | 0.3 | -6.81 | - | |||||
Net Income Margin % | 1.5 | -1.59 | 0.3 | -6.81 | - | |||||
Net Avail. For Common Margin % | 1.5 | -1.59 | 0.3 | -6.81 | - | |||||
Normalized Net Income Margin | 0.92 | -3.4 | 0.67 | -6.04 | - | |||||
Levered Free Cash Flow Margin | -2.95 | 1.7 | 5.75 | -1.02 | - | |||||
Unlevered Free Cash Flow Margin | -0.33 | 5.1 | 9.07 | 1.86 | - | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.7 | 0.67 | 0.77 | 0.79 | - | |||||
Fixed Assets Turnover | 2.09 | 2.09 | 2.5 | 2.59 | - | |||||
Receivables Turnover (Average Receivables) | 4.06 | 4.19 | 5.11 | 4.61 | - | |||||
Inventory Turnover (Average Inventory) | 1.78 | 1.6 | 1.59 | 1.83 | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.35 | 1.38 | 1.32 | 1.21 | 9.59 | |||||
Quick Ratio | 0.53 | 0.41 | 0.45 | 0.4 | 6.56 | |||||
Operating Cash Flow to Current Liabilities | 0.09 | 0.15 | 0.23 | 0.17 | -11.58 | |||||
Days Sales Outstanding (Average Receivables) | 89.87 | 87.03 | 71.59 | 79.2 | - | |||||
Days Outstanding Inventory (Average Inventory) | 205.4 | 228.7 | 229.55 | 199.63 | - | |||||
Average Days Payable Outstanding | 101.76 | 108.51 | 108.34 | 115.6 | - | |||||
Cash Conversion Cycle (Average Days) | 193.5 | 207.22 | 192.79 | 163.23 | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 79.04 | 70.81 | 59.44 | 60.87 | - | |||||
Total Debt / Total Capital | 44.15 | 41.46 | 37.28 | 37.84 | - | |||||
LT Debt/Equity | 26.76 | 21.27 | 13.12 | 6.29 | - | |||||
Long-Term Debt / Total Capital | 14.94 | 12.45 | 8.23 | 3.91 | - | |||||
Total Liabilities / Total Assets | 54.5 | 51.37 | 51.2 | 53.3 | 6.32 | |||||
EBIT / Interest Expense | 1.45 | -0.06 | 1.03 | -1.15 | -757.07 | |||||
EBITDA / Interest Expense | 2.27 | 0.65 | 1.71 | -0.34 | -601.95 | |||||
(EBITDA - Capex) / Interest Expense | 1.91 | 0.29 | 1.38 | -0.91 | -685.44 | |||||
Total Debt / EBITDA | 5.42 | 13.97 | 4.15 | -22.32 | - | |||||
Net Debt / EBITDA | 5.31 | 13.64 | 4.02 | -21.56 | 1.41 | |||||
Total Debt / (EBITDA - Capex) | 6.44 | 31.56 | 5.14 | -8.33 | - | |||||
Net Debt / (EBITDA - Capex) | 6.3 | 30.81 | 4.97 | -8.05 | 1.24 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 8.13 | -8.7 | 10.53 | -0.84 | - | |||||
Gross Profit, 1 Yr. Growth % | 15.41 | -18.24 | 32.23 | -39.38 | - | |||||
EBITDA, 1 Yr. Growth % | 43.83 | -65.98 | 183.8 | -116.98 | -243.63 | |||||
EBITA, 1 Yr. Growth % | 76.79 | -96.5 | 2.6K | -173.33 | -1.04K | |||||
EBIT, 1 Yr. Growth % | 103.23 | -105.09 | -1.89K | -195.29 | 14.15K | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -134.19 | -196.55 | -120.66 | -2.38K | -8.33K | |||||
Net Income, 1 Yr. Growth % | -134.19 | -196.55 | -120.66 | -2.38K | 157.64 | |||||
Normalized Net Income, 1 Yr. Growth % | -141.56 | -436.16 | -121.81 | -993.11 | -13.61K | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -134.15 | -196.7 | -120.37 | -2.4K | -8.85K | |||||
Accounts Receivable, 1 Yr. Growth % | 19.25 | -37.45 | 35.62 | -8.89 | - | |||||
Inventory, 1 Yr. Growth % | 10.06 | 1.42 | 6.15 | -4.41 | -99.91 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -8.05 | -9.77 | -4.98 | -3.46 | -83.67 | |||||
Total Assets, 1 Yr. Growth % | 0.11 | -8.43 | 0.08 | -6.56 | -69.64 | |||||
Tangible Book Value, 1 Yr. Growth % | 2.07 | -2.83 | 0.16 | -11.53 | -35.4 | |||||
Common Equity, 1 Yr. Growth % | 2.44 | -2.14 | 0.44 | -10.58 | -39.1 | |||||
Cash From Operations, 1 Yr. Growth % | 344.38 | 40.68 | 68.11 | -24.59 | -305.81 | |||||
Capital Expenditures, 1 Yr. Growth % | -20.07 | 20.38 | -2.15 | 48.89 | -71.97 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -123.53 | -152.75 | 272.94 | -117.61 | 512.02 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -102.09 | -1.52K | 96.66 | -79.72 | 512.12 | |||||
Dividend Per Share, 1 Yr. Growth % | - | - | - | - | - | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -16.02 | -0.64 | 0.46 | 4.7 | - | |||||
Gross Profit, 2 Yr. CAGR % | -6.31 | -2.86 | 3.98 | -12.05 | - | |||||
EBITDA, 2 Yr. CAGR % | -15.12 | -30.05 | -1.74 | -30.47 | -24.09 | |||||
EBITA, 2 Yr. CAGR % | -20.35 | -75.11 | -2.69 | 346.03 | 1.32 | |||||
EBIT, 2 Yr. CAGR % | -20.15 | -67.83 | -4.64 | 313.58 | 9.49 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -11.24 | -42.55 | -55.34 | 116.81 | 238.83 | |||||
Net Income, 2 Yr. CAGR % | -11.24 | -42.55 | -55.34 | 116.81 | 665.75 | |||||
Normalized Net Income, 2 Yr. CAGR % | -18.55 | 18.2 | -14.37 | 39.57 | 178.33 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -11.24 | -42.53 | -55.62 | 116.67 | 245.39 | |||||
Accounts Receivable, 2 Yr. CAGR % | 6.26 | -13.63 | -7.89 | 11.16 | - | |||||
Inventory, 2 Yr. CAGR % | -15.41 | 5.65 | 3.76 | 0.73 | -97.14 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -5.71 | -8.91 | -7.4 | -4.22 | -60.3 | |||||
Total Assets, 2 Yr. CAGR % | -4.72 | -4.26 | -4.27 | -3.3 | -46.74 | |||||
Tangible Book Value, 2 Yr. CAGR % | -2.4 | -0.41 | -1.35 | -5.87 | -24.4 | |||||
Common Equity, 2 Yr. CAGR % | -2.15 | 0.12 | -0.86 | -5.23 | -26.2 | |||||
Cash From Operations, 2 Yr. CAGR % | -42.26 | 150.03 | 53.79 | 12.6 | 24.58 | |||||
Capital Expenditures, 2 Yr. CAGR % | -32.48 | -1.91 | 8.54 | 20.7 | -35.4 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -38.54 | -64.77 | 40.26 | -18.83 | 132.64 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -82.89 | -45.62 | 427.55 | -36.78 | 85.28 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | - | - | - | - | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -15.67 | -13.65 | 2.95 | 0.03 | - | |||||
Gross Profit, 3 Yr. CAGR % | -7.61 | -10.47 | 7.66 | -14.16 | - | |||||
EBITDA, 3 Yr. CAGR % | -15.68 | -37.42 | 11.57 | -45.21 | 17.93 | |||||
EBITA, 3 Yr. CAGR % | -20.4 | -71.88 | 18.74 | -11.32 | 203.14 | |||||
EBIT, 3 Yr. CAGR % | -20.37 | -68.1 | 22.71 | -4.51 | 178.14 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -19.27 | -8.71 | -59.15 | 65.57 | 33.35 | |||||
Net Income, 3 Yr. CAGR % | -19.27 | -8.71 | -59.15 | 65.57 | 129.65 | |||||
Normalized Net Income, 3 Yr. CAGR % | -25.24 | 30.65 | -32.71 | 87.09 | 19.11 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -19.24 | -8.67 | -59.33 | 65.58 | 34.44 | |||||
Accounts Receivable, 3 Yr. CAGR % | -7.17 | -10.94 | 0.39 | -8.23 | - | |||||
Inventory, 3 Yr. CAGR % | -7.72 | -10.14 | 5.82 | 0.96 | -90.47 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -4.74 | -7.08 | -7.62 | -6.11 | -46.89 | |||||
Total Assets, 3 Yr. CAGR % | -4.03 | -5.97 | -2.83 | -5.04 | -34.27 | |||||
Tangible Book Value, 3 Yr. CAGR % | -0.66 | -2.55 | -0.22 | -4.87 | -16.97 | |||||
Common Equity, 3 Yr. CAGR % | -0.52 | -2.14 | 0.23 | -4.21 | -18.22 | |||||
Cash From Operations, 3 Yr. CAGR % | -26.5 | -22.3 | 119.04 | 21.27 | 37.67 | |||||
Capital Expenditures, 3 Yr. CAGR % | -13.16 | -18.12 | -1.99 | 20.6 | -25.81 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -17.39 | -41.59 | -22.64 | -29.69 | 172.54 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -66.2 | -25.46 | -16.53 | 78.17 | 89.11 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | - | - | - | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 0.3 | -4.08 | -9.56 | -6.73 | - | |||||
Gross Profit, 5 Yr. CAGR % | -1.85 | -6.47 | -3.14 | -11.1 | - | |||||
EBITDA, 5 Yr. CAGR % | -6.73 | -25.6 | -10.36 | -34.73 | -4.3 | |||||
EBITA, 5 Yr. CAGR % | -9.34 | -54.17 | -13.74 | -15.05 | 11.54 | |||||
EBIT, 5 Yr. CAGR % | -8.96 | -50.4 | -14.42 | -11.1 | 17.36 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -14.66 | -14.29 | -36.29 | 29.03 | -4.78 | |||||
Net Income, 5 Yr. CAGR % | -14.66 | -14.29 | -36.29 | 29.03 | 31.94 | |||||
Normalized Net Income, 5 Yr. CAGR % | -13.8 | 5.88 | -21.07 | 34.15 | 18.74 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -14.66 | -14.25 | -36.44 | 29.03 | -4.3 | |||||
Accounts Receivable, 5 Yr. CAGR % | -2.21 | -14.5 | -7.46 | -2.69 | - | |||||
Inventory, 5 Yr. CAGR % | -3.34 | -3.17 | -3.29 | -5.94 | -75.05 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -3.74 | -5.29 | -5.81 | -5.95 | -34.1 | |||||
Total Assets, 5 Yr. CAGR % | -1.52 | -4.28 | -4.13 | -4.91 | -23.6 | |||||
Tangible Book Value, 5 Yr. CAGR % | 1.94 | 0.05 | -0.94 | -3.89 | -10.7 | |||||
Common Equity, 5 Yr. CAGR % | 1.56 | 0.11 | -0.66 | -3.39 | -11.32 | |||||
Cash From Operations, 5 Yr. CAGR % | -13.72 | 15.45 | -1.25 | -9.88 | 74.78 | |||||
Capital Expenditures, 5 Yr. CAGR % | -14.1 | -1.95 | -5.06 | -4.37 | -17.04 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 5.43 | -19.1 | 2.09 | -33.37 | 20.23 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -43.63 | 31.61 | 1.45 | -30.21 | 14.87 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | - | - | - | - |
- Stock Market
- Stocks
- NECLIFE Stock
- Financials Nectar Lifesciences Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















